Arthur A. Torres, a director at CareDx, Inc. (NASDAQ:CDNA), has filed reports indicating the disposal of 10,570 shares of the company's common stock. These transactions resulted in a total proceeds value of approximately $214,675. The sales were executed across two distinct days, with the weighted average selling prices ranging between $19.8917 and $20.9735 per share.
The disposition began on May 14, 2026, when Mr. Torres sold 4,086 shares of common stock. The weighted average price for these initial sales was set at $20.9735 per share. Records indicate that these particular shares were transacted through multiple separate sales, with individual prices falling within the range of $20.96 to $21.03.
The following business day, May 15, 2026, saw an additional divestiture of 6,484 shares. For this second batch of sales, the weighted average price was calculated at $19.8917 per share. The individual transaction prices for these shares varied from a low of $19.73 up to $20.105.
Following the completion of both sets of sales, Mr. Torres retained ownership of 38,665 shares of CareDx, Inc. common stock. Independent analysis conducted by InvestingPro suggested that, at current market levels, the stock might be undervalued, citing a Fair Value estimate of $21.34.
These insider selling reports coincide with several significant corporate developments for CareDx, Inc., particularly concerning its financial performance in the first quarter of 2026. The company reported strong results, achieving earnings per share (EPS) of $0.34. This figure significantly surpassed the consensus expectation set by analysts, who had projected an EPS of -$0.06.
Furthermore, CareDx's total revenue reached $117.7 million. This amount exceeded the forecasted revenue of $104.12 million, representing a notable surprise of 13.04%. A key driver of this strong performance was testing revenue, which totaled $91.4 million. This segment saw an impressive year-over-year increase of 48%. In contrast, product revenue experienced a minor decline, falling by 4%. Another growth area was patient and digital solutions revenue, which climbed 33% year-over-year, reaching $16.0 million.
On the strategic front, CareDx announced plans to acquire Naveris for a total value of up to $260 million. This acquisition structure is composed of two parts: $160 million delivered in cash and an additional $100 million contingent upon achieving specific milestones. The valuation placed on Naveris was calculated at 7.6 times its trailing twelve-month revenue.
The market response to these developments has been mixed among analysts. Following the news of the acquisition, BTIG upgraded its assessment of CareDx by raising its price target to $28.00 and maintaining a 'Buy' rating. Conversely, H.C. Wainwright issued a Neutral rating on CareDx, indicating a more cautious outlook despite the company's demonstrated strong financial performance.
The combination of robust quarterly financials and major strategic acquisitions underscores significant growth momentum for CareDx in early 2026. However, the varying analyst ratings following these announcements highlight differing market perspectives regarding the sustainability of this recent upward trajectory.